{"id":"W4250712221","doi":"10.1200/jco.2004.22.14_suppl.3137","title":"A phase II clinical trial involving the use of low-dose daily oral cyclophosphamide, weekly vinblastine and rofecoxib in patients with advanced solid tumors","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Rofecoxib; Cyclophosphamide; Clinical trial; Placebo; Internal medicine; Chemotherapy; Oncology; Pharmacology; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441553,0.001679209,0.001856307,0.0006549241,0.0005149853,0.001025591,0.0009931916,0.001876368,0.005078321],"category_scores_gemma":[0.0009390201,0.0005560001,0.001031791,0.0005249825,0.001214802,0.0008264738,0.0003922775,0.003572203,0.001127037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007858272,"about_ca_system_score_gemma":0.001793251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007751029,"about_ca_topic_score_gemma":0.001653753,"domain_scores_codex":[0.9996735,0.0001430676,0.00001777293,0.00005437213,0.00002713029,0.00008416688],"domain_scores_gemma":[0.999109,0.0001614365,0.0001360664,0.00005755966,0.00005081832,0.000485129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7853112,0.116513,0.00408257,0.000892044,0.0007149142,0.0002846513,0.0002235447,0.002087627,0.02268639,0.0004276547,0.003992844,0.06278352],"study_design_scores_gemma":[0.7058544,0.2879072,0.003117418,0.00002300263,0.0001233468,0.000117958,0.00002389089,0.0007692004,0.001018713,0.0001164963,0.0009147998,0.00001353162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874021,0.001760656,0.0005277438,0.0006007134,0.0002464923,0.005870686,0.0007181207,0.00009216914,0.002781273],"genre_scores_gemma":[0.9864028,0.001622279,0.001749154,0.0009352705,0.0003409363,0.004379761,0.001706399,0.000017039,0.00284643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005078321,"threshold_uncertainty_score":0.01698864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09606544889507362,"score_gpt":0.4350126463245266,"score_spread":0.338947197429453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}